▶ ADAMAX · SUBTOPIC · MECHANISM
ADAMAX Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
EPO-derived peptide analog related to ARA-290 / cibinetide. Acts through the innate-repair-receptor (IRR) heterocomplex (EPOR + βcR). Studied for tissue-protective signaling without erythropoietic activity.
PHARMACOKINETIC HALF-LIFE
Reported half-life for ADAMAX: Short plasma (minutes). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
ADAMAX is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
Tissue repair encompasses the coordinated processes of inflammation resolution, cell migration, extracellular-matrix remodeling, and angiogenesis. Research peptides in this category include BPC-157 (pentadecapeptide cytoprotection), TB-500 (Thymosin Beta-4 actin sequestration), and GHK-Cu (copper-peptide collagen induction). The shared theme is permissive enhancement of healing processes already underway in injured tissue.
Neurotrophic signaling encompasses BDNF, NGF, and the broader neurotrophin family, acting through Trk receptor tyrosine kinases. BDNF / TrkB signaling drives synaptic plasticity, neuronal survival, and learning. Semax is the most-studied research neurotrophic peptide.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
ARA-290 and related EPO analogs are well-documented activators of the innate-repair-receptor heterocomplex (EPOR + βcR).
ARA-290 shows neuroprotective effects in rodent models of diabetic neuropathy and ischemic injury.
ARA-290 has small-cohort clinical data in sarcoidosis-related small-fiber neuropathy. Limited Western RCT data for Adamax specifically.
MECHANISM Q+A
▶ What is Adamax?
Adamax is a research-grade EPO-derived peptide analog related to ARA-290 (cibinetide). Engineered to activate the innate-repair-receptor (IRR) heterocomplex · EPOR + βcR · without stimulating red-blood-cell production.
▶ What is the innate repair receptor (IRR)?
The IRR is a heterocomplex of the EPO receptor (EPOR) and the common beta-chain receptor (βcR / CD131). It mediates the tissue-protective, anti-inflammatory, and neuroprotective biology of EPO without driving red-blood-cell production.
CITED LITERATURE
- Brines M, Patel NS, Villa P, et al.. ARA-290, a non-erythropoietic EPO analog, modulates inflammation and tissue protection. Mol Med 2014. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19